{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:08:11Z","timestamp":1783393691195,"version":"3.54.6"},"reference-count":85,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s469024","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:22:46Z","timestamp":1725549766000},"page":"621-645","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Keyuri","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-3370","authenticated-orcid":true,"given":"Khalid","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Jin","family":"Jeun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3848-535X","authenticated-orcid":true,"given":"David","family":"Nolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Psychiatry. 2022;9(2):137\u2013150.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40273-022-01217-8","volume":"41","author":"Lin","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/03007995.2020.1841618","volume":"37","author":"Crespo-Facorro","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"key":"ref6","unstructured":"World Health Organization (WHO). Psychosis, including schizophrenia; 2019. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia. Accessed September 2, 2023."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu Rev Clin Psychol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/NDT.S96392","volume":"12","author":"Karson","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neulet.2016.10.003","volume":"669","author":"Murru","year":"2018","journal-title":"Neurosci Lett"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","volume":"205","author":"Penttil\u00e4","year":"2014","journal-title":"J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2012.10.029","volume":"143","author":"Penttil\u00e4","year":"2013","journal-title":"Schizophr Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4088\/JCP.10075su1.01","volume":"72","author":"Tandon","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"ref13","first-page":"1","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"ref14","first-page":"1180","volume":"7","author":"Kaplan","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1007\/s12325-022-02232-z","volume":"39","author":"Martin","year":"2022","journal-title":"Adv Ther"},{"key":"ref16","first-page":"174","volume":"109","author":"Rethlefsen","year":"2021","journal-title":"Med Libr Assoc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.18553\/jmcp.2024.30.2.183","volume":"30","author":"Jeun","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-244X-14-53","volume":"14","author":"Awad","year":"2014","journal-title":"BMC Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12888-016-0879-5","volume":"16","author":"Awad","year":"2016","journal-title":"BMC Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/pcn.13304","volume":"76","author":"Ishigooka","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","volume":"53","author":"Rui","year":"2014","journal-title":"Neuropsychopharmacol Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/JCP.0000000000001403","volume":"41","author":"Sinkeviciute","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00213-011-2242-3","volume":"216","author":"Guo","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/NDT.S112063","volume":"13","author":"Jariyavilas","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/11599080-000000000-00000","volume":"32","author":"Rosa","year":"2012","journal-title":"Clin Drug Investig"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/POR.S64973","volume":"6","author":"Takahashi","year":"2015","journal-title":"Pragmat Obs Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17512433.2021.1865799","volume":"14","author":"Barbosa","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.psychres.2014.03.022","volume":"218","author":"Bianchini","year":"2014","journal-title":"Psychiatry Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/acps.13413","volume":"145","author":"Brodeur","year":"2022","journal-title":"Acta Psychiatr Scand"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/NDT.S130483","volume":"13","author":"De Yang","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hup.2254","volume":"27","author":"Emborg","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","volume":"3","author":"Gr\u00fcnder","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2014.07.015","volume":"158","author":"Hatta","year":"2014","journal-title":"Schizophr Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/1471-244X-12-218","volume":"12","author":"Hong","year":"2012","journal-title":"BMC Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1192\/bjo.2021.964","volume":"7","author":"Jo","year":"2021","journal-title":"BJPsych Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-244X-13-241","volume":"13","author":"Johnsen","year":"2013","journal-title":"BMC Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S0033291721001379","volume":"53","author":"Joo","year":"2023","journal-title":"Psychol Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41598-020-58078-4","volume":"10","author":"Taipale","year":"2020","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/acps.12621","volume":"134","author":"Vanasse","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.2147\/NDT.S335597","volume":"17","author":"Zhong","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.euroneuro.2013.02.003","volume":"23","author":"Bitter","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hup.2542","volume":"31","author":"Buoli","year":"2016","journal-title":"Hum Psychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11126-012-9233-3","volume":"84","author":"Chaves","year":"2013","journal-title":"Psychiatr Q"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/npr2.12247","volume":"42","author":"Hakami","year":"2022","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12913-015-0819-y","volume":"15","author":"He","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"ref46","first-page":"S83","volume":"23","author":"Klasik","year":"2011","journal-title":"Psychiatry Danub"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/PRBM.S132272","volume":"10","author":"Kongsakon","year":"2017","journal-title":"Psychol Res Behav Manag"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.2147\/NDT.S343840","volume":"17","author":"Matsuzaki","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/JCP.0000000000000993","volume":"39","author":"Sa\u011flam Aykut","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12991-017-0170-2","volume":"16","author":"Wang","year":"2017","journal-title":"Ann Gen Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40258-018-0408-4","volume":"16","author":"Barbosa","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40273-015-0348-x","volume":"34","author":"Druais","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2191-1991-2-8","volume":"2","author":"Garc\u00eda-Ruiz","year":"2012","journal-title":"Health Econ Rev"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e205888","DOI":"10.1001\/jamanetworkopen.2020.5888","volume":"3","author":"Jin","year":"2020","journal-title":"JAMA Network Open"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/NDT.S282856","volume":"17","author":"Kearns","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref56","first-page":"125","volume":"14","author":"Kim","year":"2011","journal-title":"J Ment Health Policy Econ"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3111\/13696998.2014.897627","volume":"17","author":"Lachaine","year":"2014","journal-title":"J Med Econ"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40258-015-0176-3","volume":"13","author":"Lubinga","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2753.2009.01189.x","volume":"16","author":"McIntyre","year":"2010","journal-title":"J Eval Clin Pract"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/cer-2017-0024","volume":"6","author":"N\u00e9meth","year":"2017","journal-title":"J Comp Eff Res"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1478-7547-9-6","volume":"9","author":"Phanthunane","year":"2011","journal-title":"Cost Eff Resour Alloc"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2015.08.013","volume":"70","author":"P\u0159ibylov\u00e1","year":"2015","journal-title":"J Psychiatr Res"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40273-016-0405-0","volume":"34","author":"Rajagopalan","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/JCP.0b013e318268ddc0","volume":"32","author":"Stargardt","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/13696998.2019.1580714","volume":"22","author":"Zhao","year":"2019","journal-title":"J Med Econ"},{"key":"ref66","unstructured":"All Wales Medicines Strategy group. AWMSG Secretariat Assessment Report. Lurasidone (Latuda\u00ae\u25bc) 18.5 mg, 37 mg and 74 mg film-coated tablets. United Kingdom; 2021. Available from: https:\/\/awttc.nhs.wales\/files\/appraisals-asar-far\/appraisal-report-lurasidone-latuda-1142\/. Accessed February 26, 2024."},{"key":"ref67","unstructured":"The National Health Care Institute. GVS assessment of amisulpride (Aktiprol\u00ae) for the treatment of schizophrenia. Zorginstituut Nederland, Netherlands; 2020. Available from: https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2020\/10\/21\/gvs-assessment-of-amisulpride-aktiprol. Accessed February 26, 2024."},{"key":"ref68","unstructured":"Vraylar. Significant change in YMRS total score in bipolar acute manic or mixed episodes. Available from: https:\/\/www.vraylarhcp.com\/bipolar-mania-mixed-episodes-efficacy. Accessed August 21, 2024."},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22670","volume":"22","author":"Howard","year":"2018","journal-title":"Health Technol Assess"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21490","volume":"21","author":"Barnes","year":"2017","journal-title":"Health Technol Assess"},{"key":"ref71","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Canada; 2014. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/tracking\/cdr_tracking_Latuda.pdf. Accessed February 26, 2024."},{"key":"ref72","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Pharmacoeconomic Review Report. Lurasidone hydrochloride (Latuda). Management of manifestations of schizophrenia. Canada; 2014. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0331_Latuda_PE_Report_e.pdf. Accessed February 26, 2024."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20290","volume":"20","author":"Barnes","year":"2016","journal-title":"Health Technol Assess"},{"key":"ref74","unstructured":"All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All wales medicines strategy group (AWMSG). United Kingdom; 2014. Available from: https:\/\/awttc.nhs.wales\/files\/appraisals-asar-far\/appraisal-report-aripiprazole-abilifymaintena-909\/. Accessed February 26, 2024."},{"key":"ref75","unstructured":"NIHR Health Technology Assessment Program. A systematic evaluation of the clinical and cost effectiveness of \u2018atypical\u2019 anti-psychotics in the treatment of schizophrenia. England; 2003. Available from: https:\/\/www.journalslibrary.nihr.ac.uk\/programmes\/hta\/961899\/#\/. Accessed February 26, 2024."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/13651500600973568","volume":"11","author":"Narasimhan","year":"2007","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2013.11.1.1","volume":"11","author":"Jeong","year":"2013","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"152240","DOI":"10.1016\/j.comppsych.2021.152240","volume":"108","author":"Vega","year":"2021","journal-title":"Compr Psychiatry"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-022-03895-2","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Psychiatry"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/schbul\/sbx090","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr Bull"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr Res"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1025414","DOI":"10.3389\/fpsyt.2022.1025414","volume":"13","author":"St\u0229pie\u0144-Wyrobiec","year":"2022","journal-title":"Front Psychiatry"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/95483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/95483","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:23:02Z","timestamp":1725549782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/real-world-effectiveness-economic-and-humanistic-outcomes-of-selected--peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":85,"URL":"https:\/\/doi.org\/10.2147\/ceor.s469024","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}